215 related articles for article (PubMed ID: 20368442)
1. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
Ayyoub M; Dojcinovic D; Pignon P; Raimbaud I; Schmidt J; Luescher I; Valmori D
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7437-42. PubMed ID: 20368442
[TBL] [Abstract][Full Text] [Related]
2. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
4. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
5. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.
Mizote Y; Uenaka A; Isobe M; Wada H; Kakimi K; Saika T; Kita S; Koide Y; Oka M; Nakayama E
Vaccine; 2014 Feb; 32(8):957-64. PubMed ID: 24397899
[TBL] [Abstract][Full Text] [Related]
6. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
[TBL] [Abstract][Full Text] [Related]
7. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
[TBL] [Abstract][Full Text] [Related]
8. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.
Ohkuri T; Sato M; Abe H; Tsuji K; Yamagishi Y; Ikeda H; Matsubara N; Kitamura H; Nishimura T
Cancer Sci; 2007 Jul; 98(7):1092-8. PubMed ID: 17488334
[TBL] [Abstract][Full Text] [Related]
10. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
Zeng G; Touloukian CE; Wang X; Restifo NP; Rosenberg SA; Wang RF
J Immunol; 2000 Jul; 165(2):1153-9. PubMed ID: 10878395
[TBL] [Abstract][Full Text] [Related]
11. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
13. MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.
Braendstrup P; Justesen S; Osterbye T; Nielsen LL; Mallone R; Vindeløv L; Stryhn A; Buus S
PLoS One; 2013; 8(9):e73648. PubMed ID: 24023895
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M
PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534
[TBL] [Abstract][Full Text] [Related]
15. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.
Matsuzaki J; Qian F; Luescher I; Lele S; Ritter G; Shrikant PA; Gnjatic S; Old LJ; Odunsi K
Cancer Immunol Immunother; 2008 Aug; 57(8):1185-95. PubMed ID: 18253733
[TBL] [Abstract][Full Text] [Related]
16. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
[TBL] [Abstract][Full Text] [Related]
17. Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions.
Cecconi V; Moro M; Del Mare S; Dellabona P; Casorati G
Cytometry A; 2008 Nov; 73(11):1010-8. PubMed ID: 18612991
[TBL] [Abstract][Full Text] [Related]
18. HLA class II peptide tetramers vs allergen-induced proliferation for identification of allergen-specific CD4 T cells.
Van Hemelen D; Mahler V; Fischer G; Fae I; Reichl-Leb V; Pickl W; Jutel M; Smolinska S; Ebner C; Bohle B; Jahn-Schmid B
Allergy; 2015 Jan; 70(1):49-58. PubMed ID: 25236500
[TBL] [Abstract][Full Text] [Related]
19. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.
Moro M; Cecconi V; Martinoli C; Dallegno E; Giabbai B; Degano M; Glaichenhaus N; Protti MP; Dellabona P; Casorati G
BMC Immunol; 2005 Dec; 6():24. PubMed ID: 16329759
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]